HeartWare International, Inc. (HTWR)

[cjgaddy]

1-27-12: Leerink Swann inits HTWR at Outperform/PT=95 – “Positive Inflection Point Nears, Strong Growth Ahead”…

1-27-12: ”Leerink Swann Starts Heartware Int'l (HTWR) at Outperform; Positive Inflection Point Nears, Strong Growth Ahead, PT $95”
Leerink analyst says,
"In the near term, HTWR shares could be volatile as investors await greater clarity on HVAD regulatory timelines. But, over the next 12 months, we think HTWR shares should move higher driven by:
1) Regulatory milestones, including an FDA panel and ultimate HVAD approval
2) Incremental data updates that should further mitigate HVAD thrombus concerns
3) Rapid BTT market share gains that should help drive 50%+ 2013 sales growth - over 2x the current average projected growth rate for comparable small-cap MedTech companies
4) Further pipeline progress, including first-in-man clinical trials for the next-gen MVAD, expected to begin in 1H12."
http://www.streetinsider.com/New+Coverage/Leerink+Swann+Starts+Heartware+Intl+(HTWR)+at+Outperform%3B+Positive+Inflection+Point+Nears,+Strong+Growth+Ahead/7113365.html

= = = = = = =
http://www.leerink.com/equity-research.aspx
Leerink Swann Equity Research provides unique perspectives and agenda-setting healthcare recommendations for investors. Supported by industry-based intelligence and thorough market examination, our proprietary research enables our clients to make well-informed healthcare investment decisions.

Award-Winning Equity Research
Leerink Swann has consistently been recognized for its healthcare research. Beginning in 2001, Institutional Investor has named Leerink Swann "Best of the Boutiques" in Biotechnology, Medical Supplies and Devices, Pharmaceuticals/Major, and Pharmaceuticals/Specialty. In 2006 & 2007, Leerink Swann was also ranked "Best Boutique in Health Care Technology & Distribution". In 2008 & 2009, Leerink Swann's Medical Supplies and Devices team ranked in the Institutional Investor All-American team.

The Leerink Swann Equity Research team was ranked among the top biotechnology and pharmaceutical stock pickers in The Wall Street Journal’s 2011 “Best on the Street” rankings. The team earned top honors in the 2011 FT/StarMine Analyst Awards -- #1 Stock Picker for Pharmaceuticals, #2 Stock Picker for Biotechnology and #2 Earnings Estimator in Health Care Providers & Services. 2010 accolades include #1 Biotech Stock Picker in the Wall Street Journal's "Best on the Street" special report, and #2 Earning Estimator for Health Care Providers & Services from FT/StarMine Analyst Awards.